FibroScan's evolution: a critical 20-year review

FibroScan, initially designed for assessing cheese maturity, has evolved into a crucial medical tool for liver fibrosis diagnosis. This systematic review explores its development history, functionality, and pros and cons compared to traditional liver biopsy. Precision in various clinical settings is scrutinised, emphasising FibroScan's accuracy in conditions like NAFLD and viral-induced liver disease. The article also delves into its potential in paediatrics, its relevance in monitoring COVID-19-related liver complications, and its role in predicting hepatocellular carcinoma risk, Technical aspects, including transducers, imaging integration, and portability, are examined. Various methods for evaluating liver fibrosis are discussed, highlighting FibroScan's suitability for advanced stages, contrasting with the gold standard of liver biopsy for early stages. The impact of FibroScan on long-term liver conditions is emphasised, focusing on early detection, progression monitoring, reduced invasive biopsies, and hepatocellular carcinoma risk prediction. This systematic review underscores FibroScan's transformative potential in liver disease treatment and predicts ongoing research to enhance early detection, disease monitoring, and explore new clinical applications. Anticipated advances include FibroScan-guided liver biopsy, artificial intelligence data analysis, and point-of-care device development, promising a further revolution in liver disease management. The article concludes with optimistic prospects for FibroScan's future.